AkzoNobel stock advances as UK merger review sets next test
Published on 11/12/2026 at 11:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMerger approval enters next phase
- The European Commission approved the AkzoNobel-Axalta merger subject to the divestment of AkzoNobel's European vehicle-refinish coatings business.
- The UK Competition and Markets Authority has identified a separate competition concern and set November 18 as the next remedy deadline.
- The transaction remains subject to further approvals and is still targeted for completion in early 2027.
AkzoNobel and Axalta cleared one regulatory hurdle on November 6, but the proposed merger of equals now faces a new test in the United Kingdom. The European Commission approved the transaction subject to conditions, while the UK Competition and Markets Authority raised a separate concern over vehicle-refinish coatings on November 11.
The European Commission said the companies must divest AkzoNobel's vehicle-refinish coatings business in the European Economic Area to an approved buyer. The remedy includes a dedicated manufacturing site, related assets, intellectual property, staff and transitional services. The buyer must already supply coatings or operate in a related industrial sector.
According to the European Commission, the transaction initially threatened to reduce competition in vehicle-refinish coatings across the EEA. The regulator concluded that the divestment would remove the overlap between the two companies and required an independent trustee to monitor implementation. The merger cannot proceed until a suitable purchaser has been approved.
UK deadline keeps execution risk alive
The UK CMA said its Phase 1 review found a realistic prospect that the merger could substantially lessen competition in the supply of vehicle-refinish coatings in the United Kingdom. AkzoNobel and Axalta intend to offer the same remedy package used in the EU review, including the relevant UK operations.
The companies have until November 18 to submit a remedy proposal. If the CMA accepts the undertaking, the review can move forward under the Phase 1 framework. If not, the regulator may begin a more detailed Phase 2 investigation, according to PCI Magazine.
AkzoNobel and Axalta continue to operate as separate companies. Management has maintained that the combination should close in early 2027, subject to remaining regulatory approvals and other closing conditions. The planned combination would create a coatings group with approximately 17 billion US dollars in revenue and businesses spanning powder, aerospace, refinish, mobility, marine, protective, industrial and decorative coatings.
Quote reflects a live merger backdrop
AkzoNobel stock traded at 64.06 euros on Lang & Schwarz at 11:04 CET on Thursday, November 12, 2026. The next material catalyst is the CMA remedy deadline, followed by the buyer approval process for the European vehicle-refinish business and the remaining merger clearances.
AkzoNobel stock facts
- Company: Akzo Nobel N.V.
- ISIN: NL0013267909
- Primary listing: Euronext Amsterdam
- Lang & Schwarz quote: 64.06 euros at 11:04 CET on November 12, 2026
- Merger status: EU approval subject to conditions; UK remedy review ongoing
The Dutch equity market can be followed through the AEX.
More news and analyses on AkzoNobel stock.
